Summary of significant transactions - Revised Fligotinib collaboration (Details) - Gilead - Filgotinib drug license € in Millions |
Dec. 31, 2023 |
Oct. 29, 2023 |
Dec. 31, 2022
EUR (€)
|
Jan. 31, 2021 |
|---|---|---|---|---|
| Summary Of Significant Transaction [line items] | ||||
| Total Amounts Received From Gilead In Previous Years | € 172.6 | |||
| Cost Share For Global Development Activities Terminated | 50.00% | |||
| Europe | Minimum | ||||
| Summary Of Significant Transaction [line items] | ||||
| Percentage of future net sales from 2024 | 8 | |||
| Europe | Maximum | ||||
| Summary Of Significant Transaction [line items] | ||||
| Percentage of future net sales from 2024 | 15 | |||
| Group B activities [Member] | ||||
| Summary Of Significant Transaction [line items] | ||||
| Cost Share For Global Development Activities | 50.00% |